Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia
Stopped Following regulatory consultation, the Sponsor has decided to terminate the study and analyze the current dataset. The decision to terminate was solely based on a business decision, not due to safety concerns.
Conditions
- Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
Interventions
- DRUG: Ceftazidime-avibactam
Sponsor
Pfizer
Collaborators